Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2008 1
2009 1
2010 2
2011 3
2012 6
2013 4
2014 4
2015 4
2016 8
2017 4
2018 3
2019 2
2020 4
2021 4
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group. Herold KC, et al. N Engl J Med. 2019 Aug 15;381(7):603-613. doi: 10.1056/NEJMoa1902226. Epub 2019 Jun 9. N Engl J Med. 2019. PMID: 31180194 Free PMC article. Clinical Trial.
Adverse events induced by immune checkpoint inhibitors.
Perdigoto AL, Kluger H, Herold KC. Perdigoto AL, et al. Curr Opin Immunol. 2021 Apr;69:29-38. doi: 10.1016/j.coi.2021.02.002. Epub 2021 Feb 25. Curr Opin Immunol. 2021. PMID: 33640598 Free PMC article. Review.
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.
Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC. Stamatouli AM, et al. Diabetes. 2018 Aug;67(8):1471-1480. doi: 10.2337/dbi18-0002. Epub 2018 Jun 24. Diabetes. 2018. PMID: 29937434 Free PMC article. Review.
Progress and challenges for treating Type 1 diabetes.
Garyu JW, Meffre E, Cotsapas C, Herold KC. Garyu JW, et al. J Autoimmun. 2016 Jul;71:1-9. doi: 10.1016/j.jaut.2016.04.004. Epub 2016 May 17. J Autoimmun. 2016. PMID: 27210268 Free PMC article. Review.
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.
Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. Herold KC, et al. Diabetologia. 2013 Feb;56(2):391-400. doi: 10.1007/s00125-012-2753-4. Epub 2012 Oct 21. Diabetologia. 2013. PMID: 23086558 Free PMC article. Clinical Trial.
50 results